Review

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions

T. Sagawa H. Nagashima K. Fujikawa

Aug 2026 · Journal of Gastrointestinal Cancer · Vol 57 · 0 citations · 20 references

Medicine

TL;DR

The biologic rationale, current clinical evidence, practical guideline-based positioning, practical guideline-based positioning, toxicity management considerations, resistance mechanisms, and emerging therapeutic strategies for KRAS G12C-mutated mCRC are summarized.

DOI PubMed Semantic Scholar

View source

Similar papers

Review Sep 2026

Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V

The development of MRTX1133, zoldonrasib, zoldonrasib (RMC-9805), VS-7375, RMC-5127, and daraxonrasib (RMC-6236) demonstrates that direct targeting of previously undruggable KRAS alleles is becoming clinically feasible, and anti-EGFR combination strategies particularly important in CRC.

T. Sagawa, Masahiro Hirakawa, H. Nagashima et al. · Journal of Gastrointestinal... · 1 citation

Review Aug 2026

BRAF V600E-Mutated Metastatic Colorectal Cancer: Practical Management in the Post-BREAKWATER Era

Treatment selection in the post- BREAKWATER era should integrate molecular context, patient fitness, and remaining evidence gaps, as well as the management of frail or oxaliplatin-ineligible patients, maintenance therapy, local treatment integration, and sequencing after frontline encorafenib exposure.

T. Sagawa, H. Nagashima, K. Fujikawa · Journal of Gastrointestinal... · 0 citations

Review Open access Jul 2026

Recent advances in EGFR-targeted therapies for non-small cell lung cancer

This review discusses recent advances in EGFR-targeted therapies within the molecular landscape of classical and uncommon EGFR mutations, focusing on frontline intensification strategies in metastatic disease—specifically TKI combinations with chemotherapy or bispecific antibodies or bispecific antibodies—and emerging...

L. Lucente, Lucrezia Barcellini, Beatrice Ramella Pollone et al. · Expert Opinion on Pharmacoth... · 0 citations

Review Sep 2026

Biomarker-Guided Treatment Selection in Metastatic Colorectal Cancer: A Critical Review of Established and Emerging Therapies.

This structured narrative review separately examines mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) and microsatellite-stable/mismatch repair-proficient (MSS/pMMR) disease and distinguish established treatments from investigational strategies and identify the remaining evidence gaps.

Alireza Tojjari, Shamim Pourbahrighesmat, Shahd Alkhazna et al. · Critical reviews in oncology... · 0 citations

Review Aug 2026

HER2-Targeted Therapy for Metastatic Colorectal Cancer: Current Evidence, Patient Selection, and Practical Treatment Sequencing

This narrative review focuses on the practical integration of HER2 testing and HER2-directed treatment into mCRC care and proposes a clinician-oriented framework for early patient identification, treatment sequencing, and resistance assessment.

T. Sagawa, H. Nagashima, K. Fujikawa · Journal of Gastrointestinal... · 0 citations

Review Sep 2026

Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers

The rapid evolution of KRAS-targeted therapeutic agents represents a shift from allele-specific inhibition towards a strategy that is mutation/context-dependent, thereby creating further clinical translation opportunities and increased patient benefit.

Srijita Chatterjee, S. Arya, Nidhi Sharma et al. · Medical Oncology · 0 citations